Delivery Order SPE2DB22D9239-SPE2DB25FDG63

Award Date 2/20/25
Potential Completion Date 3/13/25
Potential Value $87K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract valued at $109,272.60 to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is for the delivery of XENPOZYME 20 MG VIALS and has an ultimate completion date of April 15, 2024. This delivery order is placed under DMS Pharmaceutical Group's existing indefinite delivery contract with DLA, contract 4600082013 under the SPE2DB program, which is valued at up...
This is a $87,418.08 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The award covers the delivery of XENPOZYME 20 MG VIALS, a specialized pharmaceutical product, with a period of performance through February 10, 2023. DMS Pharmaceutical Group holds a significant $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program,...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a for-profit, woman-owned small business based in Park Ridge, Illinois. The contract, valued at $109,272.60, is for the delivery of XENPOZYME 20 MG VIALS, a pharmaceutical product. The order has an ultimate completion date of March 29, 2024 and is not set aside for any specific business category. DMS Pharmaceutical Group Inc. holds a larger indefinite delivery contract,...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $87,418.08, is for the supply of 4567363691 XENPOZYME 20 MG VIALS to support the medical supply needs of military healthcare facilities. DMS Pharmaceutical Group holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business located in Park Ridge, Illinois. The $145,696.80 award is for the delivery of XENPOZYME 20 MG VIALS, a pharmaceutical product, with a completion date of January 17, 2025. DMS Pharmaceutical Group Inc. holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which allows the agency to issue firm...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract worth $109,272.60 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the delivery of XENPOZYME 20 MG VIALS, a specialized pharmaceutical product, with a period of performance through November 6, 2024. DMS Pharmaceutical Group is a key supplier for the DLA, holding a $499,999,999 Indefinite Delivery Contract to...
The U.S. Defense Logistics Agency awarded a firm-fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business, for the supply of XENPOZYME 20 mg vials. The $109,272.60 contract has a completion date of March 19, 2024. DMS Pharmaceutical Group is a leading pharmaceutical wholesaler based in Park Ridge, Illinois that provides a wide range of branded and generic drugs to government agencies, particularly the Department of Veterans Affairs and Department of...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a for-profit, woman-owned small business. The contract has a potential value of $109,272.60 and a completion date of March 7, 2024. DMS Pharmaceutical Group will provide XENPOZYME 20 MG VIALS to fulfill the agency's pharmaceutical supply needs. This delivery order is issued under DMS Pharmaceutical Group's existing indefinite delivery contract 4600082013 with DLA,...
The federal contract award is to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $109,272.60, is a delivery order awarded by the Defense Logistics Agency (DLA) under the SPE2DB program. The contract is for the delivery of XENPOZYME 20 MG VIALS, a pharmaceutical product, with a completion date of July 19, 2024. The contract has a firm fixed price pricing type and does not have a set-aside designation. DMS...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $109,272.60 contract is for the supply of XENPOZYME 20 MG VIALS, a pharmaceutical product, with a period of performance through August 30, 2024. The award is part of a larger indefinite delivery contract (IDC) with DMS Pharmaceutical Group valued at up to $499,999,999, which runs through...
  • SPE2DB22D9239
    Indefinite Delivery Contract
  • SPE2DB22D9239-SPE2DB25FDG63
    Delivery Order

This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $87,418.08, is for the delivery of XENPOZYME 20 MG VIALS, a specialized pharmaceutical product. The contract has an ultimate completion date of March 13, 2025.

DMS Pharmaceutical Group Inc. is a key supplier in the federal pharmaceutical supply chain, providing a comprehensive range of pharmaceutical products and medical supplies to the Department of Defense (DoD) and other federal government agencies. The company holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and valid through November 2026, which enables the DLA to issue firm fixed-price delivery orders for a wide range of pharmaceutical items to support the medical supply needs of military health facilities worldwide.

Generated 5/22/25, 8:12 PM